30 Jan 2018 Innate Pharma and MedImmune enter clinical trial collaboration
29 Jan 2018 China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
29 Jan 2018 Chugai's HEMLIBRA® Gains Positive CHMP Opinion in Hemophilia A with Inhibitors
27 Jan 2018 Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
26 Jan 2018 Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
25 Jan 2018 Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-penetrating biologics
25 Jan 2018 Lilly receives EU Marketing Authorisation for Taltz® (ixekizumab) for the Treatment of Active Psoriatic Arthritis
25 Jan 2018 Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
24 Jan 2018 Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®
24 Jan 2018 MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
23 Jan 2018 Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
22 Jan 2018 Teva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic Asthma
22 Jan 2018 European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients
22 Jan 2018 Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets
22 Jan 2018 European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
22 Jan 2018 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
20 Jan 2018 U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
19 Jan 2018 Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium
19 Jan 2018 TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients
19 Jan 2018 Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, “TECENTRIQ® Intravenous Infusion 1200mg” for the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer
19 Jan 2018 First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium
19 Jan 2018 European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
18 Jan 2018 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
18 Jan 2018 GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B
18 Jan 2018 OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up